LoginRegister

    Novartis India Q3 net profit dips 31 percent to Rs 12.87 crore

    GarimaWritten by Garima   |  
    Novartis India Q3 net profit dips 31 percent to Rs 12.87 crore

    The company had posted a net profit of Rs 18.74 crore for the corresponding period of the previous fiscal, Novartis India said in a filing to BSE.


    New Delhi: Drug firm Novartis India Monday reported a 31 per cent decline in net profit to Rs 12.87 crore for the quarter ended December 2018.


    The company had posted a net profit of Rs 18.74 crore for the corresponding period of the previous fiscal, Novartis India said in a filing to BSE.


    Read Also: Novartis Kymriah wins UK backing after initial lymphoma snub

    Revenue from operations of the company stood at Rs 135.62 crore, compared with Rs 156.10 crore for the same period a year ago.


    Read Also: Novartis Aimovig not cost effective: UK price watchdog
    BSEDrug firm NovartisIndiaNew DelhiNovartisnovartis net profitrevenueShares of Novartis India
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X